Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-09
2007-01-09
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S134000, C548S135000, C548S427000, C548S439000, C548S448000, C514S411000
Reexamination Certificate
active
10484015
ABSTRACT:
A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLA2mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
REFERENCES:
patent: 0 950 661 (1999-10-01), None
patent: WO 00 07591 (2000-02-01), None
D. J., Davies, “Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent 'b!indoles, tetrahydrocarbazoles and hexahydrocyclohept 'b!indoles,”J. Med. Chem., vol. 41, No. 4, pp. 451-467 (1998); XP002215114.
Kinnick Michael Dean
Mihelich Edward David
Morin John Michael
Sall Daniel Jon
Sawyer Jason Scott
Eli Lilly and Company
Ginah Francis O.
Shameem Golam M. M.
LandOfFree
Cyclopenta[b]indole derivatives as sPLA 2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopenta[b]indole derivatives as sPLA 2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopenta[b]indole derivatives as sPLA 2 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736066